Cogstate Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Cogstate de 12.1% y 7.3% por año respectivamente. Se prevé que el BPA crezca en un 12.4% al año. Se espera que la rentabilidad financiera sea de 20.2% en 3 años.

Información clave

12.1%

Tasa de crecimiento de los beneficios

12.40%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare Services	22.8%
Tasa de crecimiento de los ingresos	7.3%
Rentabilidad financiera futura	20.15%
Cobertura de analistas	Low
Última actualización	27 Aug 2025

Actualizaciones recientes sobre el crecimiento futuro

Cogstate Limited Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next

Feb 21

Recent updates

Earnings Not Telling The Story For Cogstate Limited (ASX:CGS) After Shares Rise 27%

Sep 26

Cogstate (ASX:CGS) Is Very Good At Capital Allocation

Aug 05

Cogstate Limited's (ASX:CGS) 31% Price Boost Is Out Of Tune With Earnings

Jul 18

Cogstate Limited Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next

Feb 21

Reacquisition Of Eisai IP Will Unlock New Markets For Clinical Trials

Feb 11 Diversification into new indications and reacquisition of IP expand market opportunities, enhance revenue potential, and reduce dependency on single areas.

Cogstate Limited (ASX:CGS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Dec 14

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Aug 30

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

Jul 26

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Mar 23

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

Mar 02

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Jan 13

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Oct 04

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Sep 28

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Sep 02

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Jun 30

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

Mar 22

We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

Oct 20

Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital

Jul 23

Is Cogstate (ASX:CGS) Using Too Much Debt?

Apr 29

Previsiones de crecimiento de beneficios e ingresos

ASX:CGS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2028	66	14	13	15	2
6/30/2027	62	12	12	14	2
6/30/2026	58	10	11	14	2
6/30/2025	53	10	8	11	N/A
3/31/2025	50	9	9	11	N/A
12/31/2024	47	7	9	11	N/A
9/30/2024	45	6	7	9	N/A
6/30/2024	43	5	4	6	N/A
3/31/2024	42	5	1	3	N/A
12/31/2023	41	6	-1	0	N/A
9/30/2023	41	5	-1	1	N/A
6/30/2023	40	4	-2	1	N/A
3/31/2023	41	4	1	4	N/A
12/31/2022	41	3	4	8	N/A
9/30/2022	43	6	5	9	N/A
6/30/2022	45	8	6	10	N/A
3/31/2022	43	9	4	7	N/A
12/31/2021	42	10	2	4	N/A
9/30/2021	37	7	8	10	N/A
6/30/2021	33	5	13	16	N/A
3/31/2021	30	3	12	16	N/A
12/31/2020	28	0	11	15	N/A
9/30/2020	25	-1	4	8	N/A
6/30/2020	23	-2	-2	1	N/A
3/31/2020	21	-3	-3	0	N/A
12/31/2019	19	-3	-4	-2	N/A
9/30/2019	21	-3	-3	-1	N/A
6/30/2019	22	-2	-3	0	N/A
3/31/2019	24	-2	N/A	1	N/A
12/31/2018	27	-1	N/A	2	N/A
9/30/2018	28	-1	N/A	1	N/A
6/30/2018	29	-1	N/A	0	N/A
3/31/2018	27	-2	N/A	-1	N/A
12/31/2017	26	-3	N/A	-2	N/A
9/30/2017	26	-2	N/A	0	N/A
6/30/2017	26	-1	N/A	2	N/A
3/31/2017	26	0	N/A	3	N/A
12/31/2016	24	1	N/A	4	N/A
9/30/2016	23	1	N/A	3	N/A
6/30/2016	20	2	N/A	2	N/A
3/31/2016	19	1	N/A	1	N/A
12/31/2015	17	0	N/A	-1	N/A
9/30/2015	14	-2	N/A	-1	N/A
6/30/2015	12	-4	N/A	-2	N/A
3/31/2015	11	-3	N/A	-2	N/A
12/31/2014	10	-3	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (12.1% al año) de CGS es superior a la tasa de ahorro (3.1%).

Beneficios vs. Mercado: Se prevé que los beneficios (12.1% al año) de CGS crezcan más rápidamente que el mercado Australian (11.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de CGS crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (7.3% al año) de CGS crezcan más rápidamente que los del mercado Australian (5.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 7.3% al año) de CGS crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CGS sea alta dentro de 3 años (20.2%)

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/10/05 15:34
Precio de las acciones al final del día	2025/10/03 00:00
Beneficios	2025/06/30
Ingresos anuales	2025/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Cogstate Limited está cubierta por 2 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Elyse Shapiro	Canaccord Genuity
Dennis Hulme	Taylor Collison Limited

Cogstate Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 11%

Cogstate Limited Provides Earnings Guidance for the Second Half and Full Year Ending June 30, 2025

Cogstate Limited Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next

Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target decreased by 8.1% to AU$1.70

Recent updates

Earnings Not Telling The Story For Cogstate Limited (ASX:CGS) After Shares Rise 27%

CEO, MD & Executive Director recently bought AU$87k worth of stock

Full year 2025 earnings released: EPS: US$0.059 (vs US$0.032 in FY 2024)

Consensus revenue estimates increase by 11%

Cogstate Limited announces Annual dividend, payable on September 29, 2025

Cogstate (ASX:CGS) Is Very Good At Capital Allocation

Cogstate Limited, Annual General Meeting, Oct 16, 2025

Cogstate Limited's (ASX:CGS) 31% Price Boost Is Out Of Tune With Earnings

CEO, MD & Executive Director exercised options to buy AU$1.4m worth of stock.

Cogstate Limited Provides Earnings Guidance for the Second Half and Full Year Ending June 30, 2025

Investor sentiment improves as stock rises 26%

Cogstate Limited to Report Fiscal Year 2025 Results on Aug 22, 2025

Now 24% overvalued after recent price rise

Now 21% overvalued after recent price rise

First half 2025 earnings released: EPS: US$0.023 (vs US$0.012 in 1H 2024)

Cogstate Limited Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next

Investor sentiment improves as stock rises 19%

Reacquisition Of Eisai IP Will Unlock New Markets For Clinical Trials

Cogstate Limited to Report First Half, 2025 Results on Feb 20, 2025

Cogstate Limited (ASX:CGS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Investor sentiment improves as stock rises 15%

Cogstate Appoints Kaycee Sink as Chief Medical Officer

CEO, MD & Executive Director exercised options to buy AU$965k worth of stock.

New minor risk - Market cap size

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Non-Executive Chairman recently bought AU$108k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations

Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus revenue estimates decrease by 10%, EPS upgraded

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

If EPS Growth Is Important To You, Cogstate (ASX:CGS) Presents An Opportunity

First half 2024 earnings released: EPS: US$0.012 (vs US$0 in 1H 2023)

Price target decreased by 8.1% to AU$1.70

Investor sentiment deteriorates as stock falls 17%

The Price Is Right For Cogstate Limited (ASX:CGS)

Cogstate Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 8.6% to AU$1.85

Cogstate Limited Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Is Cogstate Limited (ASX:CGS) Trading At A 29% Discount?

Now 21% undervalued

Price target decreased by 9.0% to AU$1.70

Now 23% undervalued

Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023

Consensus EPS estimates increase by 12%

Returns Are Gaining Momentum At Cogstate (ASX:CGS)

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

Investor sentiment deteriorates as stock falls 16%

CEO, MD & Executive Director recently bought AU$100k worth of stock

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

First half 2023 earnings released: EPS: US$0 (vs US$0.024 in 1H 2022)

Consensus EPS estimates increase by 23%, revenue downgraded

Investor sentiment deteriorates as stock falls 25%

Now 24% undervalued

Cogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023

Now 22% undervalued

Cogstate Limited Announces Resignation of David Dolby as Non-Executive Director

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Price target decreased to AU$1.92

High number of new and inexperienced directors

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Price target decreased to AU$2.18

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$2.41